In last trading session, Tscan Therapeutics Inc (NASDAQ:TCRX) saw 0.49 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $2.17 trading at -$0.02 or -0.91% at ring of the bell on the day assigns it a market valuation of $115.81M. That closing price of TCRX’s stock is at a discount of -346.54% from its 52-week high price of $9.69 and is indicating a premium of 8.29% from its 52-week low price of $1.99.

For Tscan Therapeutics Inc (TCRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.12. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.28 in the current quarter.

Tscan Therapeutics Inc (NASDAQ:TCRX) trade information

Upright in the red during last session for losing -0.91%, in the last five days TCRX remained trading in the green while hitting it’s week-highest on Friday, 02/21/25 when the stock touched $2.17 price level, adding 6.87% to its value on the day. Tscan Therapeutics Inc’s shares saw a change of -28.62% in year-to-date performance and have moved 6.37% in past 5-day. Tscan Therapeutics Inc (NASDAQ:TCRX) showed a performance of -13.89% in past 30-days.

Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 81.92% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would drop -453.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -453.0% for stock’s current value.

Tscan Therapeutics Inc (TCRX) estimates and forecasts

This year revenue growth is estimated to fall -82.89% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.51M for the same. And 4 analysts are in estimates of company making revenue of 1.38M in the next quarter. Company posted 7.21M and 566k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.71% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 6.43% while estimates for its earnings growth in next 5 years are of 0.70%.

Tscan Therapeutics Inc (NASDAQ:TCRX)’s Major holders

BLACKROCK INC. is the top institutional holder at TCRX for having 4.46 million shares of worth $26.1 million. And as of 2024-06-30, it was holding 4.7034 of the company’s outstanding shares.

The second largest institutional holder is LYNX1 CAPITAL MANAGEMENT LP, which was holding about 5.22 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.6062 of outstanding shares, having a total worth of $30.56 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.37 shares of worth $2.97 million or 2.79% of the total outstanding shares. The later fund manager was in possession of 1.05 shares on Nov 30, 2024 , making its stake of worth around $2.28 million in the company or a holder of 2.14% of company’s stock.